3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Interventions
Temozolomide
47
Bevacizumab
41
Radiotherapy
17
Magnetic Resonance Spectroscopy
14
Irinotecan
11
Nivolumab
8
Everolimus
7
Radiation
6
poly ICLC
5
X-Rays
5
Phantoms, Imaging
5
Carboplatin
5
pembrolizumab
4
fluorodopa F 18
4
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Erlotinib Hydrochloride
4
Carmustine
4
ribociclib
3
palbociclib
3
ivosidenib
3
antineoplaston A10
3
Vorinostat
3
Radiotherapy, Intensity-Modulated
3
Radiosurgery
3
Modafinil
3
Lomustine
3
Biopsy
3
veliparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Glioma
×
Valacyclovir
×
Clear all
NCT00589875
2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2
Completed
52 enrolled
10 charts